Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2011 3
2012 3
2013 1
2014 1
2019 1
2021 1
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Melanoma clonal heterogeneity leads to secondary resistance after adoptive cell therapy with tumor-infiltrating lymphocytes.
König D, Sandholzer M, Uzun S, Zingg A, Ritschard R, Thut H, Glatz K, Kappos EA, Schaefer DJ, Kettelhack C, Passweg JR, Holbro A, Baur K, Medinger M, Buser A, Lardinois D, Jeker LT, Khanna N, Stenner F, Kasenda B, Homicsko K, Matter M, Rodrigues Mantuano N, Zippelius A, Läubli H. König D, et al. Among authors: baur k. Cancer Immunol Res. 2024 Apr 17. doi: 10.1158/2326-6066.CIR-23-0757. Online ahead of print. Cancer Immunol Res. 2024. PMID: 38631025
Dasatinib for treatment of CAR T-cell therapy-related complications.
Baur K, Heim D, Beerlage A, Poerings AS, Kopp B, Medinger M, Dirks JC, Passweg JR, Holbro A. Baur K, et al. J Immunother Cancer. 2022 Dec;10(12):e005956. doi: 10.1136/jitc-2022-005956. J Immunother Cancer. 2022. PMID: 36455991 Free PMC article.
Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients.
Weisser M, Khanna N, Hedstueck A, Sutter ST, Roesch S, Stehle G, Sava M, Deigendesch N, Battegay M, Infanti L, Holbro A, Bassetti S, Pargger H, Hirsch HH, Leuzinger K, Kaiser L, Vu DL, Baur K, Massaro N, Busch MP, Simmons G, Stone M, Felgner PL, de Assis RR, Khan S, Tsai CT, Robinson PV, Seftel D, Irsch J, Bagri A, Buser AS, Corash L. Weisser M, et al. Among authors: baur k. Transfusion. 2022 Oct;62(10):1997-2011. doi: 10.1111/trf.17083. Epub 2022 Sep 5. Transfusion. 2022. PMID: 36054476 Free PMC article.
[Cellular therapies].
Holbro A, Heim D, Tschan-Plessl A, Baur K, Halter JP, Buser A, Passweg JR. Holbro A, et al. Among authors: baur k. Ther Umsch. 2019;76(9):542-548. doi: 10.1024/0040-5930/a001125. Ther Umsch. 2019. PMID: 32157964 Review. German.
Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients.
Frei P, Leucht AK, Held U, Kofmehl R, Manser CN, Schmitt J, Mertens J, Rau M, Baur K, Gerlach T, Negro F, Heim M, Moradpour D, Cerny A, Dufour JF, Müllhaupt B, Geier A; Swiss Hepatitis C Cohort Study Group. Frei P, et al. Among authors: baur k. Liver Int. 2014 Apr;34(4):551-7. doi: 10.1111/liv.12279. Epub 2013 Aug 29. Liver Int. 2014. PMID: 24034338
Combined effect of 25-OH vitamin D plasma levels and genetic vitamin D receptor (NR 1I1) variants on fibrosis progression rate in HCV patients.
Baur K, Mertens JC, Schmitt J, Iwata R, Stieger B, Eloranta JJ, Frei P, Stickel F, Dill MT, Seifert B, Ferrari HA, von Eckardstein A, Bochud PY, Müllhaupt B, Geier A; Swiss Hepatitis C Cohort Study Group. Baur K, et al. Liver Int. 2012 Apr;32(4):635-43. doi: 10.1111/j.1478-3231.2011.02674.x. Epub 2011 Dec 8. Liver Int. 2012. PMID: 22151003
12 results